Systemic sclerosis: From pathogenesis to targeted therapy

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages 3-7

  Denton, Christopher P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cytokine; Fibrosis; Growth factor; Scleroderma; Systemic sclerosis; Vasculopathy

Indexed keywords

ABATACEPT; ADALIMUMAB; AMBRISENTAN; AZATHIOPRINE; BASILIXIMAB; BOSENTAN; CYCLOPHOSPHAMIDE; DASATINIB; DISITERTIDE; EFALIZUMAB; ETANERCEPT; FRESOLIMUMAB; IMATINIB; INFLIXIMAB; INTERLEUKIN 6; LYSOPHOSPHATIDIC ACID; MACITENTAN; METELIMUMAB; METHOTREXATE; MYCOPHENOLATE MOFETIL; NILOTINIB; NORLEUCINE; PAMREVLUMAB; PIRFENIDONE; RIOCIGUAT; RITUXIMAB; SELEXIPAG; TOCILIZUMAB; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; AUTACOID; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CHEMOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; FIBROSIS; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LUNG FIBROSIS; MOLECULARLY TARGETED THERAPY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK BENEFIT ANALYSIS; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; VASCULAR DISEASE; WOUND HEALING; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; REMISSION; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

ANIMALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; MOLECULAR TARGETED THERAPY; REMISSION INDUCTION; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84953343033     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. NIHTYANOVA SI, TANG EC, COGHLAN JG, WELLS AU, BLACK CM, DENTON CP: Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 2010; 103: 109-15.
2. HO YY, LAGARES D, TAGER AM, KAPOOR M: Fibrosis-a lethal component of systemic sclerosis. Nat Rev Rheumatol 2014; 10: 390-402.
3. DENTON CP, ONG VH: Targeted therapies for systemic sclerosis. Nat Rev Rheumatol 2013; 9: 451-64.
4. van LAAR JM, FARGE D, SONT JK et al.: EBMT/EULAR Scleroderma Study Group. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311: 2490-8.
5. NIHTYANOVA SI, SCHREIBER BE, ONG VH et al.: Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheum 2014; 66: 1625-35.
6. NGUYEN C, RANQUE B, BAUBET T et al.: Groupe Français de Recherche sur la Sclérodermie. Clinical, functional and health-related quality of life correlates of clinically significant symptoms of anxiety and depression in patients with systemic sclerosis: a cross-sectional survey. PLoS One 2014; 9: e90484.
7. NIHTYANOVA SI, ONG VH, DENTON CP: Current management strategies for systemic sclerosis. Clin Exp Rheumatol 2014; 32 (Suppl. 81): 156-64.
8. KHANNA D, FURST DE, ALLANORE Y et al.: Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. Rheumatology 2015; 54; 144-51.
9. HERRICK AL, LUNT M, WHIDBY N et al.: Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol 2010; 37: 116-24.
10. NIHTYANOVA SI, DENTON CP: Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 2010; 6: 112-6.
11. DISTLER A, LANG V, DEL VECCHIO T et al.: Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability. Ann Rheum Dis 2014; 73: 1264-8.
12. DERRETT-SMITH EC, DENTON CP, SONNYLAL S: Animal models of scleroderma: lessons from transgenic and knockout mice. Curr Opin Rheumatol 2009; 21: 630-5.
13. HOYLES RK, KHAN K, SHIWEN X et al.: Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model. Arthritis Rheum 2008; 58: 1175-88.
14. DERRETT-SMITH EC, DOOLEY A, GILBANE AJ et al.: Endothelial injury in a transforming growth factor β-dependent mouse model of scleroderma induces pulmonary arterial hypertension. Arthritis Rheum 2013; 65: 2928-39.
15. GILBANE AJ, DERRETT-SMITH E, TRINDER SL et al.: Impaired bone morphogenetic protein receptor II signaling in a transforming growth factor-β-dependent mouse model of pulmonary hypertension and in systemic sclerosis. Am J Respir Crit Care Med 2015; 191: 665-77.
16. DENTON CP, MERKEL PA, FURST DE et al.: Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007; 56: 323-33.
17. RICE LM, PADILLA CM, McLAUGHLIN SR et al.: Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest 2015; 125: 2795-807.
18. QUILLINAN NP, McINTOSH D, VERNES J, HAQ S, DENTON CP: Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial. Ann Rheum Dis 2014; 73: 56-61.
19. TAGER AM: Autotaxin emerges as a therapeutic target for idiopathic pulmonary fibrosis: limiting fibrosis by limiting lysophosphatidic acid synthesis. Am J Respir Cell Mol Biol 2012; 47: 563-5.
20. CASTELINO FV, SEIDERS J, BAIN G et al.: Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis Rheum 2011; 63: 1405-15.
21. TAGER AM, LACAMERA P, SHEA BS et al.: The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008; 14: 45-54.
22. de LAURETIS A, SESTINI P, PANTELIDIS P et al.: Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 2013; 40: 435-46.
23. KHAN K, XU S, NIHTYANOVA S et al.: Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis 2012; 71: 1235-42.
24. MAURER B, DISTLER A, DEES C et al.: Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors. Ann Rheum Dis 2013; 72: 2039-46.
25. KEIR GJ, MAHER TM, HANSELL DM et al.: Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J 2012; 40: 641-8.
26. PLUMBO-ZERR K, ZERR P, DISTLER A et al.: Orphan nuclear receptor NR4A1 regulates transforming growth factor-β signaling and fibrosis. Nat Med 2015; 21: 150-8.